Michal Mego1, Jozef Chovanec2, Iveta Vochyanova-Andrezalova3, Peter Konkolovsky4, Milada Mikulova5, Maria Reckova6, Vera Miskovska7, Branislav Bystricky8, Juraj Beniak6, Lenka Medvecova6, Adela Lagin9, Daniela Svetlovska3, Stanislav Spanik7, Vladimir Zajac10, Jozef Mardiak3, Lubos Drgona3. 1. 2nd Department of Oncology and National Cancer Institute, Comenius University, Faculty of Medicine, Klenova 1, 833 10 Bratislava, Slovakia. Electronic address: misomego@gmail.com. 2. Department of Oncology, St. Jacob Hospital, Bardejov, Slovakia. 3. 2nd Department of Oncology and National Cancer Institute, Comenius University, Faculty of Medicine, Klenova 1, 833 10 Bratislava, Slovakia. 4. Regional Cancer Center, Komarno, Slovakia. 5. St. Elisabeth Cancer Institute, Bratislava, Slovakia. 6. Regional Cancer Center, Poprad, Slovakia. 7. 1st Department of Oncology and St. Elisabeth Cancer Institute, Comenius University, Faculty of Medicine, Bratislava, Slovakia. 8. Department of Oncology, Trencin Hospital, Trencin, Slovakia. 9. Pharmaceutical Faculty, Comenius University, Bratislava, Slovakia. 10. Cancer Research Institute, Bratislava, Slovakia.
Abstract
PURPOSE:Diarrhea is one of the dose limiting toxicity of irinotecan. SN-38 is main irinotecan metabolite responsible for diarrhea development, which is excreted in glucuronidated form into the intestine. This study aimed to determine the effectiveness of the probiotics in the prevention of irinotecan induced diarrhea due to reduction of intestinal beta-d-glucuronidase activity. METHODS:Between January 2011 and December 2013, 46 patients with colorectal cancer starting a new line of irinotecan based therapy were included. Patients were randomized 1:1 to probiotics (PRO) or placebo (PLA). Probiotic formula Colon Dophilus™, was administered at a dose of 10×10(9)CFU of bacteria tid, orally for 12 weeks of chemotherapy. The study was prematurely terminated due to slow accrual, when 46 of 220 planned patients were accrued. RESULTS: Twenty-three patients were randomized to PRO and 23 patients to PLA. Administration of probiotics compared to placebo led to a reduction in the incidence of severe diarrhea of grade 3 or 4 (0% for PRO vs. 17.4% for PLA, p=0.11), as well as reduction of the overall incidence of diarrhea (39.1% for PRO vs. 60.9% for PLA, p=0.24) and incidence of enterocolitis (0% for PRO vs. 8.7% for PLA). Patients on PRO used less antidiarrheal drugs compared to PLA. There was no infection caused by probiotic strains recorded. CONCLUSIONS: Administration of probiotics in patients with colorectal cancer treated withirinotecan-based chemotherapy is safe and could lead to a reduction in the incidence and severity of gastrointestinal toxicity.
RCT Entities:
PURPOSE:Diarrhea is one of the dose limiting toxicity of irinotecan. SN-38 is main irinotecan metabolite responsible for diarrhea development, which is excreted in glucuronidated form into the intestine. This study aimed to determine the effectiveness of the probiotics in the prevention of irinotecan induced diarrhea due to reduction of intestinal beta-d-glucuronidase activity. METHODS: Between January 2011 and December 2013, 46 patients with colorectal cancer starting a new line of irinotecan based therapy were included. Patients were randomized 1:1 to probiotics (PRO) or placebo (PLA). Probiotic formula Colon Dophilus™, was administered at a dose of 10×10(9)CFU of bacteria tid, orally for 12 weeks of chemotherapy. The study was prematurely terminated due to slow accrual, when 46 of 220 planned patients were accrued. RESULTS: Twenty-three patients were randomized to PRO and 23 patients to PLA. Administration of probiotics compared to placebo led to a reduction in the incidence of severe diarrhea of grade 3 or 4 (0% for PRO vs. 17.4% for PLA, p=0.11), as well as reduction of the overall incidence of diarrhea (39.1% for PRO vs. 60.9% for PLA, p=0.24) and incidence of enterocolitis (0% for PRO vs. 8.7% for PLA). Patients on PRO used less antidiarrheal drugs compared to PLA. There was no infection caused by probiotic strains recorded. CONCLUSIONS: Administration of probiotics in patients with colorectal cancer treated with irinotecan-based chemotherapy is safe and could lead to a reduction in the incidence and severity of gastrointestinal toxicity.
Authors: Joanne M Bowen; Rachel J Gibson; Janet K Coller; Nicole Blijlevens; Paolo Bossi; Noor Al-Dasooqi; Emma H Bateman; Karen Chiang; Charlotte de Mooij; Bronwen Mayo; Andrea M Stringer; Wim Tissing; Hannah R Wardill; Ysabella Z A van Sebille; Vinisha Ranna; Anusha Vaddi; Dorothy Mk Keefe; Rajesh V Lalla; Karis Kin Fong Cheng; Sharon Elad Journal: Support Care Cancer Date: 2019-07-08 Impact factor: 3.603
Authors: Daniel A Schupack; Ruben A T Mars; Dayne H Voelker; Jithma P Abeykoon; Purna C Kashyap Journal: Nat Rev Gastroenterol Hepatol Date: 2021-08-27 Impact factor: 46.802
Authors: Ysabella Z A Van Sebille; Romany Stansborough; Hannah R Wardill; Emma Bateman; Rachel J Gibson; Dorothy M Keefe Journal: Curr Oncol Rep Date: 2015-11 Impact factor: 5.075
Authors: Julia E Inglis; Po-Ju Lin; Sarah L Kerns; Ian R Kleckner; Amber S Kleckner; Daniel A Castillo; Karen M Mustian; Luke J Peppone Journal: Nutr Cancer Date: 2019-01-26 Impact factor: 2.900
Authors: Alexander T Sougiannis; Brandon N VanderVeen; J Mark Davis; Daping Fan; E Angela Murphy Journal: Am J Physiol Gastrointest Liver Physiol Date: 2021-01-20 Impact factor: 4.052